| abstract |
This invention relates to an anti-Fas ligand antibodynand an assay method utilizing the anti-Fas ligand antibody.nMore specifically, this invention relates to a method fornassaying a Fas ligand in human body fluid utilizing annanti-Fas ligand antibody, and the antibody adapted for usenin such an assay. This invention also relates to an anti-Fasnligand antibody that exhibits high suppression of thenFas ligand-induced apoptosis. This invention also relatesnto a hybridoma or a cell line that produces such annantibody. n An object of the present invention is to provide annanti-Fas ligand antibody and an assay method utilizing suchnan antibody, and in particular, a method for assaying a Fasnligand in human body fluid using an anti-Fas ligandnantibody, and an antibody adapted for use in such assaynmethod. Another object of the present invention is tonprovide an anti-Fas ligand antibody exhibiting high, fornexample 50% or higher, suppression of the apoptosis inducednby the Fas ligand, and said antibody which is a humanizednantibody. A further object of the present invention is tonprovide a hybridoma and a cell line producing such annantibody. Furthermore the present invention also providesnnovel compositions or medicaments containing as annindispensable element or an active ingredient at least anynone of afore-mentioned anti-Fas ligand antibodies of theninvention, and methods of treating systemic or topicalnpathological conditions or a disease with, caused by or ninvolving the abnormality of Fas/Fas ligand system or ofnapoptosis through Fas antigen, and also involving to injectntherapeutically-effective of an anti-Fas ligand antibody tonsuppress apoptosis of Fas antigen-expressing cells into anpatient. |